SSX7
Protein SSX7
Also known as: SSX7_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7RTT5
- Gene
- SSX7
- Ensembl
- ENSG00000187754
- Chromosome
- X
- Canonical length
- 188 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nucleoli
OverviewNCBI Gene
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X;18) translocation characteristically found in all synovial sarcomas. This gene appears not to be involved in this type of chromosome translocation. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
188 residues, UniProt reviewed canonical sequence.
>Q7RTT5|SSX7
1 MNGDDAFARR PRAGAQIPEK IQKSFDDIAK YFSKKEWEKM KSLEKISYVY MKRKYEAMTK
61 LGFKATLPPF MHNTGATDLQ GNDFDNDRNQ GNQVERPQMT FCRLQRIFPK IMPKKPAEEG
121 NDSKGVPEAS GSQNDGKHLC PPGKPSTSEK INKTSGPKRG KHAWTHRLRE RKQLVIYEEI
181 SDPEEDDELocalizationUniProt · AlphaFold · HPA
Whether an antibody against SSX7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.63
- Highest tissue expression
- 0.6 nTPM
Expression across tissuesHPA
Tissue
- retina: 0.6 nTPM
- esophagus: 0.3 nTPM
- salivary gland: 0.3 nTPM
- skin: 0.3 nTPM
- bone marrow: 0.2 nTPM
- cerebral cortex: 0.2 nTPM
Single-cell type
- early primary spermatocytes: 0.9 nCPM
- early spermatids: 0.6 nCPM
- differentiating spermatogonia: 0.4 nCPM
- foveolar cells: 0.4 nCPM
- late spermatids: 0.4 nCPM
- basal keratinocytes: 0.2 nCPM
Immune cell
- neutrophil: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- white matter: 7.9 nTPM
- cerebellum: 6.1 nTPM
- pons: 5.1 nTPM
- medulla oblongata: 5 nTPM
- cerebral cortex: 4.8 nTPM
- basal ganglia: 4.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.82
- gnomAD pLI
- 0
- gnomAD missense Z
- -1.97
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SSX7 as an antibody target. Whether an autoantibody or antibody against SSX7 could matter depends on whether native SSX7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SSX7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Source-annotated serology context
The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.
- They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy.
Loading the interactive Seroatlas protein explorer...